259793-96-9
favipiravir
CAS: 259793-96-9
Molecular Formula: C5H4FN3O2
259793-96-9 - Names and Identifiers
| Name | favipiravir |
| Synonyms | favipiravir Favipiravir 6-fluoro-3,4-dihydro-3-oxo-Pyrazinecarboxamide Pyrazinecarboxamide, 6-fluoro-3,4-dihydro-3-oxo- (9CI) |
| CAS | 259793-96-9 |
| EINECS | 1533716-785-6 |
259793-96-9 - Physico-chemical Properties
| Molecular Formula | C5H4FN3O2 |
| Molar Mass | 157.1025632 |
| Density | 1.78±0.1 g/cm3(Predicted) |
| Boling Point | 552.6℃ at 760 mmHg |
| Storage Condition | -20℃ |
| Use | Application of fapilavir can be used for influenza A and B antiviral therapy. Studies have shown that, in addition to influenza Virus, the drug also on a variety of RNA Virus showed a good anti Virus activity, such as Ebola Virus Virus, sand Virus, Bunia Virus, rabies Virus and so on. |
259793-96-9 - Research progress of new antiviral drugs favipiravir
from VIP
Author:
Wei Na , Wang Cai-Xia , Liu Xibao , qu Huixin
Abstract:
Favipiravir is an anti-Virus drug with a new mechanism of action so far. It inhibits Virus proliferation by selectively blocking Virus nucleic acid replication, and is clinically used to treat new and recurrent influenza. This paper reviews the mechanism of action, pharmacology, pharmacokinetics, toxicology, adverse reactions, drug interactions and clinical evaluation of favipiravir.
Key words:
favipiravir; Antiviral; nucleic acid replication inhibitors
DOI:
10.3870/j.issn.1004-0781.2016.02.016
cited:
year:
2016
Last Update：2024-01-02 23:10:35
259793-96-9 - Synthesis of favipiravir
from hownet
Author:
Wang Huan , Lee boat , Zhong Wu
Abstract:
aminomalonic acid Diethyl ester hydrochloride by free and ammonolysis amino malonamide, and glyoxal ring synthesis of 3-oxo-3, 4-dihydropyrazine-2-carboxamide (T1105), and then by bromination, chloro-simultaneous amide dehydration, halogen exchange to 3, 6-difluoropyrazine-2-carbonitrile, followed by Selective hydrolysis of the 3-position fluoride, finally, the cyano group was hydrolyzed to amide to obtain antiviral drug favipiravir, and the total yield was about 9%.
Key words:
favipiravir T705 RNA polymerase inhibitor antivirals synthesis
DOI:
10.13220/j.cnki.jipr.2015.02.018
cited:
year:
2014
Last Update：2023-08-16 22:09:08
259793-96-9 - Analysis of domestic and foreign literatures favipiravir for viral infectious diseases
from VIP Journal Professional Edition
Author:
Su Na , Liu Ying , Chen Xiaoyi , Wei Chunyan , He Zhiyao
Abstract:
objective to search favipiravir studies on infectious diseases in Virus, evaluate the efficacy and safety of favipiravir, and provide reference for the treatment of new favipiravir Coronavirus Virus (Pneumonia) in COVID-19. Methods the Ovid EMBase,Ovid Medline,Ovid CENTRAL and CNKI databases were searched and included in the clinical studies favipiravir for infectious diseases Virus, and descriptive analysis was performed. Results a total of 265 literatures were initially examined, covering 23 kinds of Virus. After screening, 11 clinical studies of favipiravir treatment of infectious diseases Virus were included, involving 5 kinds of Virus diseases: Influenza (influenza) 4, ebola (EBO) hemorrhagic fever 3, severe Fever and thrombocytopenia syndrome (SFTS)1, Lassa (LAS) hemorrhagic fever 1, new Coronavirus Virus Pneumonia (COVID-19)1, one safety study. The results of the study showed that favipiravir for influenza, EBO,SFTS,LAS,COVID-19 clinical efficacy is better, which for COVID-19 of the study results show that favipiravir of the treatment group Virus median time to turn negative 4 d(IQR: 11 d(IQR:8~13) of the control group was significantly lower than that of the control group (2.5~9) (P<0.001). Conclusion There are few reports of clinical studies favipiravir, and there are many animal and cell studies. Clinical studies show that it has good curative effect and can be recommended for the treatment of COVID-19.
stowed
Key words:
favipiravir COVID-19 viral infectious diseases
DOI:
10.3870/j.issn.1004-0781.2020.07.009
year:
2020
Last Update：2023-08-16 22:09:08
Supplier List
Product Name: favipiravir Request for quotation
CAS: 259793-96-9
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 259793-96-9
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Spot supply
Product Name: Favipiravir (T-705) Visit Supplier Webpage Request for quotationCAS: 259793-96-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: Favipiravir Request for quotation
CAS: 259793-96-9
Tel: +86-571-88162785
Email: Lucy@verypharm.com
Mobile: +86-13606544505
QQ: 472954302
Product List: View Catalog
CAS: 259793-96-9
Tel: +86-571-88162785
Email: Lucy@verypharm.com
Mobile: +86-13606544505
QQ: 472954302
Product List: View Catalog
Product Name: favipiravir Request for quotation
CAS: 259793-96-9
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 259793-96-9
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Spot supply
Product Name: Favipiravir (T-705) Visit Supplier Webpage Request for quotationCAS: 259793-96-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: Favipiravir Request for quotation
CAS: 259793-96-9
Tel: +86-571-88162785
Email: Lucy@verypharm.com
Mobile: +86-13606544505
QQ: 472954302
Product List: View Catalog
CAS: 259793-96-9
Tel: +86-571-88162785
Email: Lucy@verypharm.com
Mobile: +86-13606544505
QQ: 472954302
Product List: View Catalog
View History